浩鼎生技股份有限公司

🔬 OBI Pharma Showcases Biomarker Advances at APAC Summit 🚀 At the 2024 APAC Companion Diagnostics & Liquid Biopsy Summit in Singapore, OBI Pharma highlighted innovations in precision oncology. Biomarkers are transforming cancer research by optimizing drug development, patient selection, and clinical trial success. Dr. Ming-Chen Yang presented on advancing biomarkers from preclinical to clinical stages, showcasing OBI-822, a breast cancer immunotherapy in Phase III trials. Using the Globo H biomarker, this trial selects patients more likely to benefit, enhancing trial success. #OBIPharma #PrecisionMedicine #HealthcareInnovation  #CDx #CompanionDiagnostics #Biomarkers #LiquidBiopsy https://lnkd.in/gjkvUZH7

🌟 OBI CareerMatters: Storytelling in Action, Part 2 🌟 This session featured six enthusiastic volunteers, each presenting their stories and receiving real-time feedback from our CEO, Dr. Heidi Wang. Here are some standout insights from the session: 1️⃣ Slide Numbering: Include slide numbers to guide your audience and allow easy referencing during your presentation.  2️⃣ Image Accuracy: Use images that are both relevant and accurately reflect the content being discussed.  3️⃣ Clear Headers: Use headers that clearly convey your key messages, making it easier for your audience to follow along.  4️⃣ Minimize Filler Words: Limit verbal fillers to enhance clarity and maintain engagement. Dr. Wang's constructive feedback encouraged each presenter and reinforced our belief that storytelling is a crucial skill for elevating professional communication. Stay tuned for more insights in our upcoming leadership sessions!  Follow our LinkedIn page for updates on future events 🔥💼 #OBI #CareerMatters #StorytellingSkills #EffectiveCommunication #ProfessionalGrowth

🚀 OBI Pharma Showcases Innovation at the World ADC Event Series Conference! 🚀 Dr. David Teng-Yi Huang, our Director and Head of Medicinal Chemistry, has been invited to present at the prestigious 15th World ADC San Diego conference! 🌎 💡 Key Highlights: 💪 GlycOBI® ADC Platform 💪 Proprietary Linker Technology Follow us and stay updated on our journey toward transforming cancer care. 🌐 #OBIPharma #GlycOBI® #ADCPlatform #BiotechInnovation #WorldADC https://lnkd.in/gscu4ecC

🤝 #浩鼎 與 輔仁大學 於10月25日簽署產學合作備忘錄(Memorandum of Understanding, MOU) ，共同推動生技創新與人才培育！ 在輔大醫學院國璽樓的簽約儀式中，雙方攜手建立產學合作計畫，幫助學生深入了解生技產業的多樣性與挑戰，並為新藥研發注入更多創新動力。🚀 🔗 關注 #OBIPharma #IndustryAcademiaCollaboration #MOU #TalentDevelopment #DrugDevelopment #BiotechInnovation 🤝 On October 25, OBI Pharma and Fu Jen Catholic University signed an MOU to encourage biotechnology innovation and nurture talent! Held at Fu Jen's College of Medicine, Paul Cardinal Shan Medical Building, the signing ceremony established a partnership aimed at providing students with an in-depth view of the biotech industry's diversity and challenges, infusing fresh momentum into drug development. 🚀 🔗 Follow #OBIPharma https://lnkd.in/gFDsUdVp

🚀 OBI Pharma is making waves on the global stage! 🌍 We're thrilled to announce that OBI Pharma will Showcase Research Achievements and Cutting-Edge ADC Platform Technology at several prestigious international conferences over the next six months. 🗓️ Upcoming Highlights: • World ADC San Diego (Nov 4-7, 2024): Dr. David Teng-Yi Huang will showcase OBI’s innovations in ADC development. • World Companion Diagnostics & Liquid Biopsy Summit APAC (Nov 13-14, 2024): Dr. Michelle Yang will discuss the latest in companion diagnostics. • 15th World ADC London (Mar 3-6, 2025): CEO Dr. Heidi Wang will lead a workshop on maximizing ADC therapeutic index and engage in a panel on precision medicine. Additionally, Dr. Ming-Tain Lai, OBI’s Chief Scientific Officer, and Dr. David Teng-Yi Huang will give talks at separate sessions during this major event. • ADC Asia Congress 2025 (Mar 12-13, 2025): Dr. Wang will address challenges and opportunities in ADC development. • Novel Conjugates Summit (Mar 25-27, 2025): Dr. Dong Xu will present on innovations in novel conjugates. Dr. Wang emphasizes that these engagements highlight our commitment to advancing ADC technology and fostering collaboration within the industry. We look forward to connecting with peers and driving innovation together! 💡🤝 #OBIPharma #ADCTechnology #Biotechnology #Research #Innovation #GlobalConferences #PrecisionMedicine #Collaboration https://lnkd.in/gEQv2htg

🎀 粉紅十月 響應乳癌防治 浩鼎出動志工 🎀 在粉紅十月，台灣浩鼎參與了2024年TBCA「點亮雙色粉紅絲帶 定期乳篩 健康愛(I)閃耀」活動。10月20日（星期日），我們在國父紀念館映池西側廣場，與關心乳癌防治的夥伴們齊聚一堂，共同為台灣女性的健康發聲。儘管當天細雨，志工們的熱情不減。 浩鼎的團隊以行動全力支持了這項意義重大的活動： 📣 成功宣導乳篩重要性：浩鼎的志工在廣場與大量民眾互動，通過問答遊戲，成功向參與者傳遞乳癌篩檢和自我檢查的關鍵知識。 🤝 全程協助活動順利進行：浩鼎的志工團隊全程協助TBCA大會流程推動，從現場整隊到道具發放，確保了活動的順利圓滿。 💪 員工積極參與：浩鼎的員工踴躍參與志工服務，響應乳癌防治。 讓我們為這次活動的成功喝采，同時也期待未來繼續同心響應，用愛和行動點亮更多希望！🎀 #OBIPharma #TBCA #PinkRibbon #Social #ESG #breastcancerawarenessmonth  #earlydetection 🎀 Pink October: OBI Pharma Volunteers Support Breast Cancer Prevention 🎀 During Pink October, OBI Pharma participated in TBCA's 2024 "Light Up Dual Pink Ribbons - Regular Breast Screening for Healthy and Radiant Life" campaign. On Sunday, October 20th, we gathered with partners who care about breast cancer prevention at the west plaza of the Sun Yat-sen Memorial Hall. Despite the light rain, volunteers' enthusiasm remained undampened. OBI Pharma's team actively supported this meaningful event through: 📣 Breast screening awareness: Our volunteers interacted with numerous participants in the plaza, effectively conveying key knowledge about breast cancer screening and self-examination through Q&A games. 🤝 Full event support: OBI Pharma's volunteer team assisted with TBCA's program throughout the event, from crowd management to prop distribution, ensuring smooth execution. 💪 Active employee participation: OBI Pharma employees enthusiastically volunteered to support breast cancer prevention. Let's celebrate the success of this event while looking forward to continuing our united response, lighting up more hope through love and action! 🎀

📢 OBI CareerMatters: Mastering the Art of Storytelling (Part 1)  🎨 Our CEO, Dr. Heidi Wang, just delivered an inspiring talk on "Storytelling" as part of our OBI CareerMatters series. Here are some golden nuggets: 1️⃣ Craft impactful presentations: 3 key points per slide, use visuals, simplify your wording. 2️⃣ Storyboarding: Organize thoughts, identify issues early 3️⃣ Email mastery: Clear subject lines, concise content, proper etiquette   At OBI, we believe great storytelling ignites passion and drives success! 🔥💼 Eager to learn more? Stay tuned for Part 2! 👉 Follow our LinkedIn page for updates #OBI #CareerMatters #Storytelling #ProfessionalDevelopment #CorporateCommunication

🌟[Event Spotlight]🌟 An insightful BATBA Coffee Chat ☕️🎙️featuring our CEO, Dr. Heidi Wang! 📅 Nov. 3rd, 4-5:30 PM PT / Nov. 4th, 8-9:30 AM Taipei Time Dr. Wang will share her unique journey: 💡 Transitioning from 30 years in US Big Pharma to Taiwan's biotech landscape 💡 Navigating innovation in global and local contexts 💡 OBI Pharma's vision for the future This virtual event offers an opportunity to learn from Dr. Wang's extensive experience and gain her perspective on Taiwan's thriving biotech industry. #Biotech #PharmaceuticalLeadership #TaiwanInnovation #OBIPharma #BATBA

🏆Congratulations to our partners at Ascentawits Pharma for receiving the "Outstanding Paper Award" at CSCO! OBI Pharma's partner, Ascentawits Pharma Ltd., presented promising interim results for AST-3424 (OBI-3424) at #CSCO2024: Phase II study in advanced hepatocellular carcinoma (HCC) Median OS: 10.8 months (12.3 months for 2nd line+) ORR: 6.7%, DCR: 60.0% Potential new option for late-line HCC patients Key highlights: ✅ Encouraging survival benefits ✅ Good safety profile ✅ Effective in patients who progressed after immunotherapy AST-3424, a first-in-class AKR1C3-activated prodrug developed by OBI Pharma, shows promise for HCC patients with limited options. OBI Pharma continues to collaborate closely with Ascentawits through the sharing of clinical data and information. #OBI3424 #CancerResearch #ClinicalTrials #LiverCancer #Partnership https://lnkd.in/gEd4bubg

Remarkable news 🎉 OBI-992, our innovative cancer-fighting therapy, has been recognized as a top contender in the global fight against cancer! 📌Key highlights: 🌟Selected from over 1,000 nominations submitted 🌟Shortlisted as 1 of 8 "2024 Most Promising Clinical Candidates"  🌟Targeting gastric and lung cancers with unique advantages 🌟Potential to overcome current treatment limitations *Reference: https://lnkd.in/g8jJX4-E This recognition fuels our mission to revolutionize cancer care and bring hope to patients worldwide. Want to learn more about how we're shaping the future of cancer treatment? 👉 Visit our website  👉 Follow our LinkedIn page for updates #ADCAwards2024 #CancerBreakthrough #OBIPHARMA #TROP2ADC #FutureOfOncology https://lnkd.in/gcXbz2Bt